Atea Pharmaceuticals — Third Quarter 2026 Earnings Summary

Atea Pharmaceuticals reported positive topline results from its Phase 3 C-BEYOND trial, demonstrating that the bemnifosbuvir/ruzasvir (BEM/RZR) regimen achieved statistical non-inferiority to Epclusa in treating chronic Hepatitis C virus infection. The company anticipates receiving top-line data from its parallel Phase 3 C-FORWARD trial in early 2027 to support a New Drug Application submission targeted for mid-2027. Additionally, Atea secured a non-dilutive credit facility with Hercules Capital for up to $200 million, having drawn $65 million to fund operations through mid-2028. The company also advanced its Hepatitis E program, completing the single ascending dose portion of a Phase 1 study for its potential first-in-class treatment, AT-587.